Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids.
ACSL
CP: Cancer
CP: Metabolism
STAT3 acetylation
anti-apoptosis
chemoresistance
fatty acid oxidation
mitochondrial membrane potential
phospholipids
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
18
03
2021
revised:
16
03
2022
accepted:
04
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
Overcoming resistance to chemotherapies remains a major unmet need for cancers, such as triple-negative breast cancer (TNBC). Therefore, mechanistic studies to provide insight for drug development are urgently needed to overcome TNBC therapy resistance. Recently, an important role of fatty acid β-oxidation (FAO) in chemoresistance has been shown. But how FAO might mitigate tumor cell apoptosis by chemotherapy is unclear. Here, we show that elevated FAO activates STAT3 by acetylation via elevated acetyl-coenzyme A (CoA). Acetylated STAT3 upregulates expression of long-chain acyl-CoA synthetase 4 (ACSL4), resulting in increased phospholipid synthesis. Elevating phospholipids in mitochondrial membranes leads to heightened mitochondrial integrity, which in turn overcomes chemotherapy-induced tumor cell apoptosis. Conversely, in both cultured tumor cells and xenograft tumors, enhanced cancer cell apoptosis by inhibiting ASCL4 or specifically targeting acetylated-STAT3 is associated with a reduction in phospholipids within mitochondrial membranes. This study demonstrates a critical mechanism underlying tumor cell chemoresistance.
Identifiants
pubmed: 35649368
pii: S2211-1247(22)00645-3
doi: 10.1016/j.celrep.2022.110870
pii:
doi:
Substances chimiques
Fatty Acids
0
Membrane Lipids
0
Phospholipids
0
Acetyl Coenzyme A
72-89-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
110870Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests H.Y. has patent applications related to cell-penetrating peptide. Y.-J.L. and H.Y. serve as consultants at Inova BioTherapeutics, Inc.